Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
891.7 USD | +0.96% | -0.73% | +1.74% |
04-26 | Regeneron Faces Q1 Seasonality Despite Eylea HD Launch, Oppenheimer Says | MT |
04-26 | Oppenheimer Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,125 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.74% | 95.28B | |
-2.10% | 103B | |
+2.74% | 22.15B | |
-16.13% | 21.02B | |
-8.42% | 18.15B | |
-41.01% | 16.73B | |
-14.93% | 16.05B | |
+4.48% | 13.68B | |
+34.09% | 12.17B | |
-23.21% | 8.24B |
- Stock Market
- Equities
- REGN Stock
- News Regeneron Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals' Revenue Slides, Still Tops Street Views as R&D Spending Picks Up